Alsertib (MLN8237) and Brentuximab Vedotin for Relapsed/Refractory CD30-Positive Lymphomas and Solid Malignancies

NCT02780011 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped lack of funding

Conditions

CD30-positive Lymphoma
CD30-positive Solid Tumor

Interventions

DRUG: Brentuximab Vedotin
DRUG: Alsertib

Sponsor

Eric Bernicker, MD

Collaborators

[object Object]
[object Object]